Meta-analysis to determine the clinical impact of axillary lymph node dissection in the treatment of invasive breast cancer.

Abstract:

:There are divergent opinions regarding the optimum surgical management of the axilla in patients with invasive breast cancer. Guidelines mandate axillary lymph node dissection (ALND) in the setting of positive sentinel lymph nodes. However, recent studies have questioned the true benefits of this procedure. Therefore, a meta-analysis of relevant randomized trials was performed in order to clarify the oncological benefit of axillary lymph node dissection. A comprehensive search of published randomized trials that compared patients with primary operable breast cancer with/without ALND was performed using MEDLINE, and available data were cross-referenced. Reviews of each study were conducted, and data were extracted. Primary outcomes were overall survival and recurrent axillary disease. A total of 7347 patients with operable primary breast cancer were identified from 8 randomised controlled trials comparing axillary recurrence in patients with or without ALND. Six of these trials provided data on overall survival on 6895 patients. Overall survival favours patients having ALND (OR = 1.22 (95% CI 1.03-1.44, p = 0.02). Similarly, patients undergoing ALND had increased recurrence-free survival (OR = 2.25 (95% CI 1.28-3.94, p = 0.0047). ALND appears to positively impact on overall and recurrence-free survival from breast cancer. These data highlight the enduring benefits of ALND in an era where adjuvant therapies are being promoted to manage regionally advanced/metastatic disease.

authors

Joyce DP,Manning A,Carter M,Hill AD,Kell MR,Barry M

doi

10.1007/s10549-015-3549-2

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

235-40

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

153

pub_type

杂志文章,meta分析,评审
  • The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

    abstract::The basal-like or basal phenotype (BP) class of breast cancers have recently attracted attention as a poor prognostic form of breast cancer. However, BP appears to encompass biologically and clinically heterogeneous tumours, resulting in a lack of consensus definition of BP. We analysed 48,000 gene transcripts in 132 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0450-x

    authors: Zhang H,Rakha EA,Ball GR,Spiteri I,Aleskandarany M,Paish EC,Powe DG,Macmillan RD,Caldas C,Ellis IO,Green AR

    更新日期:2010-05-01 00:00:00

  • Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

    abstract::We analyzed the p53 mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53 with fluorescence in situ hybridization (FISH). A functional yea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023351717408

    authors: Concin N,Zeillinger C,Tong D,Stimpfl M,König M,Printz D,Stonek F,Schneeberger C,Hefler L,Kainz C,Leodolter S,Haas OA,Zeillinger R

    更新日期:2003-05-01 00:00:00

  • Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.

    abstract:PURPOSE:The results of studies comparing survival in familial and sporadic breast cancer (BC) are inconsistent. A higher incidence of contralateral breast cancer (CBC) has been reported in familial BC. Ascertainment bias may influence both the reported familial CBC and survival. DESIGN:We assessed CBC incidence, dista...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9054-2

    authors: Tilanus-Linthorst MM,Bartels KC,Alves C,Bakri B,Crepin E,van den Ouweland A,Klijn JG,Meijers-Heijboer H,Brekelmans CT

    更新日期:2006-01-01 00:00:00

  • HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

    abstract:BACKGROUND:Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-019-05303-y

    authors: Jerusalem G,Lancellotti P,Kim SB

    更新日期:2019-09-01 00:00:00

  • HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer.

    abstract::miRNAs regulate the expression of genes in both normal physiology and disease. While miRNAs have been demonstrated to play a pivotal role in aspects of cancer biology, these reports have generally focused on the regulation of single genes. Such single-gene approaches have significant limitations, relying on miRNA expr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3004-9

    authors: Pillai MM,Gillen AE,Yamamoto TM,Kline E,Brown J,Flory K,Hesselberth JR,Kabos P

    更新日期:2014-07-01 00:00:00

  • Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer.

    abstract:PURPOSE:Little is known about racial variations in the financial impact of cancer care. Using data from a national survey of racially diverse patients with metastatic breast cancer, we examined racial/ethnic patterns in employment and cost-management (i.e., financial coping) behaviors. METHODS:We conducted an online s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05449-9

    authors: Samuel CA,Spencer JC,Rosenstein DL,Reeder-Hayes KE,Manning ML,Sellers JB,Wheeler SB

    更新日期:2020-01-01 00:00:00

  • Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

    abstract:BACKGROUND:Women affected with breast cancer who carry a BRCA1 or BRCA2 (BRCA1/2) mutation are at risk of developing contralateral breast cancer. To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in additio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9423-5

    authors: Graves KD,Peshkin BN,Halbert CH,DeMarco TA,Isaacs C,Schwartz MD

    更新日期:2007-09-01 00:00:00

  • T-Type voltage gated calcium channels: a target in breast cancer?

    abstract:PURPOSE:The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-018-4970-0

    authors: Bhargava A,Saha S

    更新日期:2019-01-01 00:00:00

  • Rho proteins and cancer.

    abstract::The Rho family of GTPases has been intensively studied for their roles in signal transduction processes leading to cytoskeletal-dependent responses, including cell migration and phagocytosis. In addition, they are important regulators of cell cycle progression and affect the expression of a number of genes, including ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/B:BREA.0000018423.47497.c6

    authors: Ridley AJ

    更新日期:2004-03-01 00:00:00

  • New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.

    abstract:PURPOSE:Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs it...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4380-8

    authors: Alshaker H,Wang Q,Srivats S,Chao Y,Cooper C,Pchejetski D

    更新日期:2017-10-01 00:00:00

  • Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer.

    abstract:PURPOSE:Myeloperoxidase (MPO) is an enzyme secreted by neutrophil granulocytes as a result of phagocytosis during inflammation. In colorectal cancer, tumour infiltration by MPO expressing cells has been shown to be independently associated with a favourable prognosis. In this study, we explored the role of MPO-positive...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05336-3

    authors: Zeindler J,Angehrn F,Droeser R,Däster S,Piscuoglio S,Ng CKY,Kilic E,Mechera R,Meili S,Isaak A,Weber WP,Muenst S,Soysal SD

    更新日期:2019-10-01 00:00:00

  • Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

    abstract:PURPOSE:The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database. METHODS:The NCDB was queried fo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05243-7

    authors: Weiss A,Lin H,Babiera GV,Bedrosian I,Shaitelman SF,Shen Y,Kuerer HM,Mittendorf EA,Caudle AS,Hunt KK,Hwang RF

    更新日期:2019-07-01 00:00:00

  • Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

    abstract::Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2223-1

    authors: Niraula S,Dowling RJ,Ennis M,Chang MC,Done SJ,Hood N,Escallon J,Leong WL,McCready DR,Reedijk M,Stambolic V,Goodwin PJ

    更新日期:2012-10-01 00:00:00

  • Thrombocytosis as a prognostic factor in inflammatory breast cancer.

    abstract:PURPOSE:Platelets are essential components of hemostasis and also play an important role in the tumor microenvironment. The purposes of our research were to examine the role of thrombocytosis in inflammatory breast cancer (IBC) and to know which cytokine drives thrombocytosis. METHODS:We reviewed the medical records o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4463-6

    authors: Harano K,Kogawa T,Wu J,Yuan Y,Cohen EN,Lim B,Reuben JM,Ueno NT

    更新日期:2017-12-01 00:00:00

  • Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

    abstract::Tumour hypoxia, being widespread in solid tumours, is related to an increased risk of invasion and metastasis as well as to resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor-1alpha (HIF-1alpha) has emerged as the key regulator of the cellular response to hypoxia. In primary breast cancers, HIF-1alp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9589-5

    authors: Smollich M,Götte M,Kersting C,Fischgräbe J,Kiesel L,Wülfing P

    更新日期:2008-03-01 00:00:00

  • 99m-Tc-tetrofosmin scintigraphy for the evaluation of suspicious palpable and non-palpable breast lesions.

    abstract:PURPOSE:To assess the value of 99m-Tc-tetrofosmin (tetrofosmin) scintigraphy in patients with palpable and nonpalpable breast lesions. PATIENTS AND METHODS:Prospective, blinded trial. One hundred and fifty-nine consecutive patients with 163 breast lesions detected by clinical examination and mammography were included....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006442622417

    authors: Obwegeser R,Berghammer P,Muellauer-Ertl S,Kubista E,Sinzinger H

    更新日期:2000-08-01 00:00:00

  • Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

    abstract:PURPOSE:This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET. METHODS:We conducted a re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4501-4

    authors: Nyrop KA,Deal AM,Lee JT,Muss HB,Choi SK,Wheless A,Carey LA,Shachar SS

    更新日期:2018-01-01 00:00:00

  • Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

    abstract:BACKGROUND:We report a novel BRCA1 LGR, involving the complete duplication of exon 3, in an Italian patient with a strong family history of breast and ovarian cancer. Our purpose is to provide an effective characterization of this LGR using a combination of different methods able to establish the exact breakpoints of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4275-8

    authors: Concolino P,Rizza R,Hackmann K,Paris I,Minucci A,De Paolis E,Scambia G,Zuppi C,Schrock E,Capoluongo E

    更新日期:2017-07-01 00:00:00

  • Hormones and hormone receptors in the etiology of breast cancer.

    abstract::Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:

    authors: Thomas DB

    更新日期:1986-01-01 00:00:00

  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).

    abstract::Current evidence suggests that the majority of DCIS lesions do not progress to invasive carcinoma, and overtreatment of DCIS is a significant problem. We previously reported an 8-gene signature that differentiated microdissected low-grade (LG) DCIS lesions with and without associated stromal invasion, based on differe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3838-4

    authors: Geradts J,Groth J,Wu Y,Jin G

    更新日期:2016-06-01 00:00:00

  • Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue.

    abstract::We have qualitatively evaluated the retention of the fluorescent dye rhodamine 123 by malignant or non-malignant breast epithelial cells in passively-infused fresh surgical specimens. Our findings demonstrate a microscopically-visible increase in the ability of primary and metastatic tumor cells to retain the dye, as ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01975444

    authors: Dairkee SH,Hackett AJ

    更新日期:1991-03-01 00:00:00

  • Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

    abstract::Ductal carcinoma in situ (intraductal carcinoma) of the breast is a commonly recognized and curable clinical entity. Patients with intraductal carcinoma are at risk to develop invasive breast cancer presumably due to a transition from the noninvasive to the invasive phase of growth. Primary breast malignancies commonl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00689717

    authors: Iglehart JD,Kerns BJ,Huper G,Marks JR

    更新日期:1995-06-01 00:00:00

  • A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk.

    abstract::In this paper, we report findings from a family-based association study examining the association between polymorphisms in two key estrogen-metabolism genes CYP1B1 (codon 432 G --> C and codon 453 A --> G variants) and COMT (codon 158 G --> A variant) and female breast cancer. We conducted the study among 280 nuclear ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000025401.60794.68

    authors: Ahsan H,Chen Y,Whittemore AS,Kibriya MG,Gurvich I,Senie RT,Santella RM

    更新日期:2004-05-01 00:00:00

  • Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.

    abstract::In previous studies, we observed that regulation of expression of CD200, both on cells of a transplantable breast cancer, EMT6, and of the host, as well as of the receptor, CD200R in host mice, regulated local tumor growth and metastasis in immunocompetent animals. This in turn led to an improved ability to document i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2735-3

    authors: Gorczynski RM,Chen Z,Khatri I,Podnos A,Yu K

    更新日期:2013-11-01 00:00:00

  • Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.

    abstract:PURPOSE:The prognosis of elderly patients with hormone receptor-positive breast cancer is very good, and their survival is unaffected by performing breast-conserving surgery (BCS) without radiotherapy. Therefore, we aimed to verify that BCS without axillary lymph node dissection, sentinel lymph node biopsy, or radiothe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05686-3

    authors: Zhong Y,Xu Y,Zhou Y,Mao F,Lin Y,Guan J,Shen S,Pan B,Wang C,Peng L,Huang X,Li Y,Wang X,Sun Q

    更新日期:2020-07-01 00:00:00

  • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

    abstract::The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n =...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3115-3

    authors: Nilsson MP,Hartman L,Kristoffersson U,Johannsson OT,Borg A,Henriksson K,Lanke E,Olsson H,Loman N

    更新日期:2014-10-01 00:00:00

  • Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.

    abstract::To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006167210269

    authors: Tomita S,Deguchi S,Miyaguni T,Muto Y,Tamamoto T,Toda T

    更新日期:1999-01-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract::The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1429-y

    authors: Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期:2011-06-01 00:00:00

  • Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.

    abstract:PURPOSE:Fiber rich foods and dairy products have been suggested to be associated with breast cancer prognosis, though existing research is limited and either report on pre- or post-diagnostic dietary intake in relation to breast cancer prognosis. We investigated the associations between intake of whole grain (WG) and d...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05497-1

    authors: Andersen JLM,Hansen L,Thomsen BLR,Christiansen LR,Dragsted LO,Olsen A

    更新日期:2020-02-01 00:00:00

  • Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).

    abstract::Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(6...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-008-9894-7

    authors: Kahán Z,Spanik S,Wagnerova M,Skacel T,Planko B,Fitzthum E,Lindner E,Soldatenkova V,Zielinski CC,Brodowicz T

    更新日期:2008-12-01 00:00:00